Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans.

Department of Pathology, University of Washington Medical Center, Seattle, WA 98195, USA.
Journal of Clinical Oncology (Impact Factor: 17.88). 10/2002; 20(17):3586-91. DOI: 10.1200/JCO.2002.01.027
Source: PubMed

ABSTRACT Dermatofibrosarcoma protuberans is caused by activation of the platelet-derived growth factor B (PDGFB) receptor, a transmembrane tyrosine kinase. We investigated the response of dermatofibrosarcoma protuberans to the tyrosine kinase inhibitor imatinib mesylate.
A patient with unresectable, metastatic dermatofibrosarcoma protuberans received imatinib mesylate (400 mg bid). Response to therapy was assessed by [18F]fluorodeoxyglucose (FDG) positron emission tomography, magnetic resonance imaging, and histopathologic and immunohistochemical evaluation.
The patient was treated for 4 months with imatinib mesylate. The hypermetabolic uptake of FDG fell to background levels within 2 weeks of treatment, and the tumor volume shrank by over 75% during the 4 months of therapy, allowing for resection of the mass. There was no residual viable tumor in the resected specimen, indicating a complete histologic response to treatment with imatinib mesylate.
Imatinib mesylate is highly active in dermatofibrosarcoma protuberans. The dramatic response seen in this patient demonstrates that inhibition of PDGFB receptor tyrosine kinase activity can significantly impact viability of at least one type of solid tumor.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dermatofibrosarcoma Protuberans (DFSP) is a rare skin tumor, characterized by frequent local recurrence but is seldom metastatic. It is histologically characterized by storiform arrangement of spindle cells. Cytogenetically, most tumors are characterized by translocation 17:22 leading to overexpression of tyrosine kinase PDGFB which can be targeted with tyrosine kinase inhibitor, Imatinib. We describe the first case of unresectable pancreatic metastases from DFSP treated with neoadjuvant Imatinib and subsequently R0 metastectomy. Additionally, a comprehensive systematic review of DFSP pancreatic metastases and the current published data on the use of Imatinib in DFSP is summarized.
    Clinical sarcoma research. 01/2014; 4:8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Niedermolekulare synthetische Moleküle (small molecules) haben in jüngster Zeit erhebliches Interesse für die Behandlung solider Tumoren gefunden. Sie richten sich vorwiegend gegen Rezeptoren der Signaltransduktion (Tyrosinkinasen, EGF), die für die Proliferation bei manchen Subtypen maligner Tumoren von entscheidender Bedeutung sind. Während die EGF-Rezeptorblockade hinsichtlich der dadurch gebotenen therapeutischen Optionen noch schwer abschätzbar ist, hat die Blockade von c-kit, einem homologen Stammzellfaktor bei der CML und bei gastrointestinalen Stromatumoren, bereits einen festen Stellenwert erreicht. Die Beeinflussung von PDGF-, von VEGF- oder anderen Rezeptoren beruht meist auf der Blockade der kristallografisch ermittelten Struktur der Kinasedomäne mit Behinderung der Phosphorylierung. Das Medikamenten-Engineering ist hierbei von entscheidender Bedeutung, aber auch die Subklassifikation von Malignomen, um tatsächlich denjenigen Tumortyp zur Behandlung zu bringen, bei dem der blockierbare Rezeptor einen oder den entscheidenden Schritt der Tumorproliferation darstellt. Hierfür sind Genexpressionsstudien auf der Basis von Mikroarrays eine wichtige Voraussetzung. Da unklar ist, wie lange eine Rezeptorblockade anhält, sollte bei Resektabilität des Residualtumors der operative Eingriff angestrebt werden. Zu berücksichtigen ist, dass für Operationen unter den Bedingungen der Rezeptorblockade noch wenige Erfahrungen vorliegen. Die Aufklärung der Resistenzmechanismen gegenüber small molecules hat für die CML und GIST gerade begonnen und verspricht wichtige Aufschlüsse über intratumorale Anpassungsvorgänge an medikamentöse Rezeptorblockaden zu liefern.
    Der Onkologe 01/2004; 10(1). · 0.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: Aggressive fibromatosis (AF) is a rare benign monoclonal fibroblastic proliferation which accounts for 0.03% of all neoplasms and 3% of all soft tissue sarcomas. It can occur sporadically or within the context of Gardner’s syndrome and at any age, although it is more common among young patients.Areas covered: AF is characterised by a natural history that is highly unpredictable; these tumours are benign, in the sense that they do not metastasize, but are locally aggressive, with a high risk of recurrence. Therefore, the management of patients with fibromatosis is challenging and controversial. Surgery, radiotherapy, medical treatment and chemotherapy have been used for AF. Here, the management of AF is reviewed, considering all the known and possible new therapeutic options, in a view of a multidisciplinary management of the patient.Expert opinion: An upfront watchful waiting policy is largely accepted as an initial strategy for management of this disease. Medical treatments should be considered for all the patients who progressed clinically and/or radiologically. The first step should be a hormonal and/or NSAID treatment, followed by systemic chemotherapy or targeted agents. Surgery does play a role where feasible and without undue morbidity, or after other treatment failure. For abdominal wall AF, surgery should be the recommended first-line treatment. As for other rare cancers, careful counselling at a referral centre is mandatory, as well as a multidisciplinary management of the patient.
    Expert Opinion on Orphan Drugs. 08/2014;